MyDosageBeta
About us № 01 · Manifesto, signed

Realtalk — why this
market looks the way it is.

Patents, cost, access and the gray market — laid out plainly, by a small independent team in Copenhagen.

§ I — The premise

Peptides are not new and they are not exotic. A lot of them already exist in nature — some are already in your body. And here is the thing that explains almost everything else: you generally cannot patent a molecule that already exists in nature. No patent, no twenty-year monopoly, no way to recover a billion dollars in trials. So the easy conclusion is “that is why pharma does not care.”

But pharma is not the enemy. Companies like Novo Nordisk and Eli Lilly are the ones actually funding the science — running the trials, doing the safety work, building the road the rest of us get to drive on. That deserves credit, not resentment.

§ II — The hard part

What they can patent is the hard part: engineering a more stable molecule, or solving delivery. Peptides fall apart easily, which is why getting one into a pill that survives your stomach and still works is a genuine feat. Rybelsus is the live example — the molecule is engineered and protected, and the technology that lets you swallow it instead of injecting it is a separate innovation. That is real R&D, and it costs real money.

So where is the friction? Cost and access. The price and the barriers climbed so high that, for a lot of people, access fell out of proportion to need. That is what fuels the anti-pharma feeling — and it bites hardest here, because some of these peptides have been used for years, and now the people who relied on them cannot reach them.

That gap is where the gray market grows. People who want a piece of it, who feel entitled to it — because in their eyes it is not some brand-new invention, just a known compound. And that is where the tension sits: pharma on one side, compounding pharmacies in the middle, the open market on the other.

— we are not picking a side. just laying out the map.

§ III — Who we are

MyDosage is built by an independent team based in Copenhagen, Denmark. We are a company, not a collective or a forum: there is a registered legal entity behind the site, and it is the same entity named as data controller in our privacy policy.

We are not owned, funded or sponsored by anyone in the peptide industry — no brand, no compounding pharmacy, no lab supplier, no telehealth clinic. That is the whole point. The moment a supplier can buy a better score, the score is worth nothing.

Want the mechanics instead of the intent? Read how we check — the criteria, the caps on brand-supplied documents, and the dispute process.

§ IV — How we handle evidence

We organise what is actually known, so you can make your own call.

  1. 01

    Clinical evidence

    Closed trials. Strict rules.

    Comes from closed clinical trials run under specific, consistent rules. Because the rules are so consistent, this evidence can be reviewed and rated the same way every time. We have done that work — you see the ratings directly.

  2. 02

    Real-world evidence

    Messier. Shaped by context.

    Shaped by environment and conditions outside the clean boundaries of a trial. Still valuable, but harder to compare head to head.

  3. 03

    User experience

    Real people. Real stories.

    Real people telling you what happened to them. It matters — but you cannot draw clinical conclusions from it, and we will not pretend you can.

Why does the distinction matter so much? Because clinical evidence exists for a specific reason. Regulators deciding how to spend public money need a very high, very specific bar before they will fund something. That is a completely different question from asking a friend how something made them feel. Both are real. They just answer different things.

Here is what we add: we take user experience seriously enough to give it its own layer of evidence — clearly labelled as exactly what it is. Not dressed up as a trial. Just shown honestly, next to the clinical picture, so you can see both and decide for yourself how far to lean in or lean out. That decision is always yours.

§ V — The human piece

And there is a human piece to this. It matters most when someone feels hopeless, or hits a strange side effect, and then finds another person who has been through the exact same thing. That connection can be powerful. So we connect you.

This is an ambitious thing to do well: precise enough to be trusted, simple enough that you actually use it on a Tuesday morning.

What we stand for
  1. 01

    Free for the person taking it

    Checking a brand, following a plan and keeping your record costs nothing. Suppliers pay only for transparency tooling — never for position or for a better score.

  2. 02

    No paid placement

    Nothing on this site is sponsored today. Every listing carries a sponsored flag that is false, so if that ever changes you will see it on the listing itself.

  3. 03

    Calibrated, not certain

    We show what we checked, when we checked it, and what we could not verify. A missing answer is written as missing, not smoothed over.

  4. 04

    Listing is not endorsement

    We map the three ways people actually get peptides. Mapping a way is not a recommendation to walk through it.

The longer version — how we think about evidence, and why we refuse to be prescriptive — is in the manifesto.

in closing —

That is our purpose. That is what you are contributing to just by being here. Thank you for that — we hope you find it useful, and we are always open to feedback.

End of Vol. I